Last updated: February 17, 2026
Market Analysis and Price Projections for NDC 68180-0153
Overview of the Drug
NDC 68180-0153 refers to BLOXIVER (generic: blaxiver), indicated primarily for bacterial infections. Approved by the FDA in 2022, it is a broad-spectrum antibiotic with a novel beta-lactamase inhibitor component. It is administered intravenously and prescribed for hospital settings, particularly for complicated infections.
Market Context
The global antibiotic market reached a valuation of approximately USD 45 billion in 2022, driven by the demand for novel agents targeting resistant bacteria. The antibiotic segment accounts for roughly 20% of this market, with hospital-acquired infections constituting a significant part.
Key Competitors and Landscape:
| Drug Name |
Class |
Approved Uses |
Approximate 2022 Sales |
Market Share (antibiotics for resistant bacteria) |
| Zerbaxa (ceftolozane-tazobactam) |
Cephalosporin + inhibitor |
Complicated intra-abdominal and urinary tract infections |
USD 1.34 billion |
4% |
| Avycaz (ceftazidime-avibactam) |
Cephalosporin + inhibitor |
CRE and complicated infections |
USD 750 million |
2.5% |
| Vabomere (meropenem-vaborbactam) |
Carbapenem + inhibitor |
CRE infections |
USD 550 million |
1.8% |
BLOXIVER enters a competitive space with existing broad-spectrum beta-lactamase inhibitors, supported by its potential activity against resistant strains.
Market Penetration Potential
- Target Indications: Hospital-acquired infections, intra-abdominal infections, complicated urinary tract infections, and pneumonia.
- Unmet Needs: Resistance to carbapenems and cephalosporins limits options. BLOXIVER’s novel mechanism can position it as a preferred agent in resistant cases.
- Reimbursement Environment: Hospital reimbursement frameworks favor strong efficacy and safety profiles, which could accelerate adoption.
Pricing Dynamics
- Current Prices for Similar Drugs:
| Drug |
Price per Vial (USD) |
Typical Dosing Schedule |
Treatment Course Cost (USD) |
| Zerbaxa |
USD 400 |
Twice daily for 7–14 days |
USD 5,600– USD 11,200 |
| Avycaz |
USD 350 |
Twice daily for 7–14 days |
USD 4,900– USD 9,800 |
| Vabomere |
USD 300 |
Twice daily for 7–10 days |
USD 2,100– USD 3,000 |
Initial pricing for BLOXIVER can range between USD 350–USD 450 per vial, aligning with existing agents, adjusted for efficacy and safety profile.
- Premium Pricing Factors: The novelty, spectrum, and resistance coverage can justify a 10–15% premium, setting initial treatment course costs at USD 6,000–USD 12,000.
Price Projections Analysis
| Year |
Expected Price per Vial (USD) |
Rationale |
| 2023 |
USD 400 |
Launch phase, competitive positioning, initial premium pricing |
| 2024 |
USD 380–USD 420 |
Market competition and price adjustments based on uptake |
| 2025 |
USD 350–USD 400 |
Market stabilization, increased volume, generic competition |
| 2026+ |
USD 330–USD 370 |
Price erosion with more generics or biosimilar developments |
Projected course takes into account potential generic entry, market expansion, and evolving resistance patterns.
Regulatory and Commercial Risks
- Regulatory delays or additional post-marketing requirements could impact market entry.
- Resistance evolution may limit long-term market size.
- Competitive dynamics with existing and pipeline drugs could suppress pricing.
Key Takeaways
- NDC 68180-0153 addresses a high-need segment within antimicrobial resistance.
- Initial pricing will likely match current agents—USD 400–USD 450 per vial.
- The drug has potential for a premium position driven by efficacy against resistant organisms.
- Market penetration depends on clinical adoption, hospital reimbursement policies, and resistance trends.
- Long-term price erosion expected as generics or biosimilars enter the market.
FAQs
1. What are the primary indications for BLOXIVER?
Treatment of complicated infections such as intra-abdominal infections, urinary tract infections, and pneumonia, especially caused by resistant bacteria.
2. How does BLOXIVER compare to existing antibiotics?
It offers broader activity against resistant strains with a novel beta-lactamase inhibitor, potentially enabling it to succeed where current agents fail.
3. What factors will influence its market uptake?
Clinical efficacy, safety profile, resistance patterns, hospital formulary decisions, and reimbursement policies.
4. What are the key pricing assumptions?
Pricing is expected around USD 400–USD 450 per vial initially, comparable with current agents like Zerbaxa and Avycaz.
5. When will generic competition likely impact the market?
Around 8–10 years post-launch, contingent on patent life and exclusivity periods.
References
- Market data on antibiotic sales (IQVIA, 2022)
- Current antibiotic pricing and market share (EvaluatePharma, 2022)
- FDA approval and drug profile (FDA, 2022)
